Spotlight – still plenty of hopefuls in lung fibrosis
Roche’s zinpentraxin alfa is out of the running, but Bristol, Blade, Pliant and others have contenders in the mid-stage idiopathic pulmonary fibrosis pipeline.
Esmo 2021 movers – a handful of biotech winners emerge
Leap and Innate were clear winners on the stock market during the medical meeting, while Astrazeneca’s strong performance stands out among the large caps.
GW succumbs to a Jazz overture
A focus on rare diseases and regulatory acceptance of cannabis make GW the subject of a $7.2bn buyout.
Ash 2020 movers – shorts roasting on an open fire
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Ash 2020 – UK biotech's hollow victory
Results with Loxo-305 could justify Lilly’s acquisition of Loxo, but its inventor, the UK’s Redx, can just read ‘em and weep.
Verastem plays the Kras card
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.
